The AACU joined thirteen other organizations in asking the House and Senate appropriations committees to allocate $60 million in FY24 for the Kidney Cancer Research Program (KCRP) at the Congressionally Directed Medical Research Programs (CDMRP) conducted by the US Department of Defense. The CDMRP’s highly innovative research drives scientific discovery in high-impact research areas, (including kidney cancer) not sponsored by the National Institutes of Health (NIH) and other federal agencies.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.